Eurofins Divests MET Labs Division to UL Solutions for 575 Million Euros
Eurofins Scientific has announced the signing of an agreement to divest its Electrical & Electronic Testing division (MET Labs) to UL Solutions Inc. for an enterprise value of 575 million euros. This divestiture marks a strategic turning point for the group, refocusing on its core life testing activities.
MET Labs, the divested business, is an international network of laboratories specializing in product safety testing, inspection, and certification for the consumer electronics, automotive, telecommunications, and industrial sectors. The division employs about 1,300 staff worldwide and is expected to generate more than 180 million euros in revenue by 2026, with profitability largely in line with the group's average.
Strategic Refocus and Use of Proceeds
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Eurofins states that this divestiture is part of its strategy to refocus on its core life testing activities. The group plans to allocate the proceeds from this sale to several priorities: debt reduction, capital expenditures for owned laboratories and sites, development of next-generation digital solutions, robotics and artificial intelligence, share buybacks, and strategic acquisitions to strengthen its leadership positions in the markets for food, environmental, pharmaceutical, clinical, and related testing.
The completion of the transaction remains subject to customary regulatory approvals and is expected before the end of the year 2026. The press release does not specify any potential specific financial or operational impacts related to the divestiture, nor the detailed conditions of the transition.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
